Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04467723
Title Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors University of Kansas Medical Center
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab + Pirfenidone

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST